United States

Protalix Biotherapeutics Inc (PLX.A)

PLX.A on American Stock Exchange

3:38pm EDT
Change (% chg)

$0.01 (+1.55%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for PLX.A


Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system (ProCellEx). The Company has developed taliglucerase alfa (marketed under the name Uplyso in Brazil and certain other... (more)


Beta: 0.81
Market Cap(Mil.): ₪245.54
Shares Outstanding(Mil.): 99.81
Dividend: --
Yield (%): --


  PLX.A Industry Sector
P/E (TTM): -- 39.80 37.05
EPS (TTM): -1.16 -- --
ROI: -47.43 -5.86 14.35
ROE: -- -4.70 15.56

BRIEF-Protalix Biotherapeutics initiates PRX-102 global phase III clinical trial

* Initiates PRX-102 global phase III clinical trial of fabry disease to support United States and European filings Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

Jun 06 2016

BRIEF-Protalix Biotherapeutics reports Q1 loss per share of $0.09

* Cash and cash equivalents as of march 31, 2016 were $66.7 million, to be sufficient to finance activities into 2018

May 09 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : New Constructs, LLC
Provider : Thomson Reuters Stock Report
Provider : ValuEngine, Inc.
Provider : Reuters Investment Profile
Provider : Ford Investor Services, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.